Syn­log­ic, Gink­go ex­pand mi­cro­bial dis­cov­ery pact, throw­ing $80M in­vest­ment in­to the mix

For Gink­go Bioworks, team­ing up with Syn­log­ic on a pi­lot dis­cov­ery project late 2017 marked its for­ay in­to har­ness­ing the ther­a­peu­tic abil­i­ty of its cell pro­gram­ming plat­form. Hav­ing since leaped in­to a new an­tibi­otics ef­fort with Roche, Gink­go is anti­ng up $80 mil­lion to go deep­er with Syn­log­ic.

The two com­pa­nies, both based in the Cam­bridge/Boston hub, are un­veil­ing a new col­lab­o­ra­tion in which Gink­go will help op­ti­mize the mi­cro­bial strains that Syn­log­ic — a pi­o­neer in reengi­neer­ing non-path­o­gen­ic bac­te­ria in­to med­i­cines — has iden­ti­fied as vi­able drug can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER